At 5-12 weeks of gestation the amniotic sac is surrounded by celomic fluid, which contains cells of fetal origin. This fluid can be sampled by celocentesis, which involves the ultrasound-guided insertion of a needle through the vagina. The aim of this study was to examine the feasibility of prenatal diagnosis of haemoglobinopathies from the celomic fluid using a specific protocol. Celocentesis was performed at 7-9 weeks gestation in 26 singleton pregnancies at risk for haemoglobinopathies. In 25 cases more than 30 fetal cells were recovered from the celomic fluid and in all these cases molecular analysis for haemoglobinopathies was possible and the results were confirmed by subsequent chorionic villus sampling or amniocentesis. The results of this study suggest that reliable diagnosis of thalassemia syndromes can be performed from 7 weeks gestation by celocentesis. Further work is necessary to demonstrate the safety of celocentesis before widespread use.
Haemoglobinopathies are a major public health problem worldwide (Weatherall, 2010) . ß-thalassemia and haemoglobin disorders account for 3AE4% of deaths in children <5 years of age (Modell & Darlison, 2008) . Prevention of thalassemia major can be achieved by population screening in combination with prenatal diagnosis (Rosatelli et al, 1986; Harteveld et al, 2009) .
Prenatal diagnosis of chromosomal disorders and genetic abnormalities necessitates the analysis of fetal material obtained by chorionic villus sampling (CVS) at 11-13 weeks gestation or amniocentesis from 16 weeks onwards. An alternative technique for earlier diagnosis is celocentesis (Jurkovic et al, 1993; Makrydimas et al, 1997 Makrydimas et al, , 2002 Makrydimas et al, , 2004 . At 5-12 weeks gestation the amniotic sac is surrounded by celomic fluid (CF), which contains cells of fetal origin (Jurkovic et al, 1993; Renda et al, 2010) . This fluid can be sampled by a technique that involves the ultrasound-guided insertion of a needle through the vagina from as early as 6 weeks. The desirability of such technique is not only based on the feasibility of achieving prenatal diagnosis several weeks earlier than with CVS but also on the potential for in-utero stem cell transplantation before the fetus becomes immunologically competent. However, studies investigating the feasibility of prenatal diagnosis from fetal DNA extracted from cells in the CF reported failure rates of more than 40%, which was attributed to the small number of celomic cells, the high degree of maternal contamination and the unknown nature of the maternal and fetal cells in CF (Jouannic et al, 2006 (Jouannic et al, , 2008 .
In this study we present a CF-specific protocol that maximizes the success rate of prenatal genetic testing using this fluid.
Materials and methods
The institutional review board approved the study, which complied with the declaration of Helsinki and the participating couples provided written informed consent (Hospital Ethical Committee authorization on date 26 January 2005, No 80). The patients included in this study are part of an ongoing investigation examining the safety of celocentesis. 
Sampling
Celocentesis was carried out at 7-9 weeks gestation in 26 singleton uncomplicated pregnancies at risk for haemoglobinopathies, including 15 for b-thalassemia, nine for Sickle-Cell/ beta-thalassemia and two for b-thalassemia and Hb Lepore Boston (Table I ). The procedure was offered to all women seeking prenatal diagnosis of haemoglobinopathy at our centre. The procedure, performed by the same operator (George Makrydimas), essentially involved transvaginal sonography and the insertion of a 20 G needle through the fornix into the celomic cavity (Fig 1; Makrydimas et al, 2002) . Samples of CF were aspirated into three different syringes (0AE2, 0AE2 and 0AE6 ml). The first two samples were discarded to reduce the risk of contamination by maternal blood and the third sample was used for analysis.
Microscopical observation
An aliquot of CF (50 ll) was put in a petri disk and observed by optical microscopy to assess the number and composition of cells as previously reported (Renda et al, 2010) .
Purification
The CF samples in which the percentage of maternal cells were more than 5% of the total cell content were purified using anti-CD45 and anti-CD105 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) for negative selection. The CF sample was placed in an Eppendorf tube and centrifuged at 400 g for 10 min. The pellet was then dissolved in 50 ll of phosphate-buffered saline (PBS) and 2AE5 ll each of anti-CD 45 anti-CD 105 MicroBeads (Miltenyi Biotec) were added and prior to incubation at 4°C for 15 min. Subsequently, PBS (500 ll) was added to the tube and centrifuged at 400 g for 10 min and the pellet re-dissolved in PBS (550 ll). The sample was then applied to a MiniMACS separation column (Miltenyi Biotec) and all the liquid containing fetal cells (negative selection) was eluted into a clean Eppendorf tube. The pellet of cells was collected by centrifugation at 13400 g for 10 min, dissolved in 50 ll of 5% IstaGene Matrix (Bio-Rad Laboratories, Hercules, CA, USA) and incubated at 56°C for 30 min and at 95°C for 10 min. The supernatant (45 ll) containing DNA was removed and transferred to a Eppendorf tube (0AE5 ml volume). 
Maternal contamination control
Maternal contamination of the CF sample was evaluated before and after negative selection of maternal cells using a very sensitive multiplex fluorescence PCR (QF-PCR), containing primers for highly variable microsatellites of many chromosomal markers (STR) 13, 18, 21, X and Y (D13S631, D13S634, D13S258, D18S535, D18S386, D21S1435, D21S1411, D21S1414, AMXY, X22, HPRT, DXS6803, DXS6809). Products were denatured and fragments of different sizes were run on ABI PRISM 3130 DNA Analyser (Applied BioSystems). Data were analysed by GeneScan software (Applied BioSystems) (Fig 2) . 
Results

Sampling
Aspiration of CF was possible in all cases and was not associated with a change in fetal heart rate. The volume of the CF sample used for diagnosis was 450-710 ll (Table I) . On the basis of previous investigations (data not shown), only samples containing more than 30 fetal cells were considered adequate for molecular analysis and this was achieved in 25 of our 26 cases. One sample contained only 10 cells was considered inadequate for further analysis.
Microscopical observation
The presence of megaloblastic and other cells was observed, as previously reported (Fig 3; Renda et al, 2010) . Surface antigens were characterized as CD71+ (fetal cells), CD45+ (maternal white cells) and CD105+ (mesenchymal/endothelial cells). The total number of fetal cells, estimated manually in a Burker chamber, was 10-6400 (Table I) .
Purification
The CF samples were considered appropriate for molecular prenatal HBB without preventive purification in seven cases. The other 18 CF showed reduction of contamination to <1%, after negative selection of maternal cells.
Molecular analysis
This was conducted in 25 of the 26 samples. PCR amplification of DNA was proportional to the number of observed embryofetal erythroid cells (Renda et al, 2010) . In nine cases the fetus was affected by thalassemia major and sickle-cell/beta-thalassemia and the parents decided to terminate the pregnancies. Ten and six were carriers and normal, respectively. Molecular analysis of prenatal diagnosis was confirmed by CVS or amniocentesis at 12 or 16 weeks gestation. Moreover, molecular diagnosis was also confirmed on placental tissue following pregnancy termination in those cases with affected fetuses.
Discussion
This study has established a specific protocol for the assessment and analysis of CF samples that has made it possible to achieve accurate prenatal diagnosis during the embryonic stage of intrauterine life. The critical components of the protocol were firstly, expertise in obtaining CF samples and discarding the first samples with high maternal contamination, secondly, microscopical examination of the CF sample immediately after celocentesis to estimate the total number of fetal cells, and thirdly, purification of the sample to minimize the number of maternal cells. The findings of the study confirm our previous results that CF contains embryo-fetal erythroid precursors, megaloblasts (CD 71+/CD 45)) and maternal white cells (CD 45+) (Renda et al, 2010) . All CF samples showing maternal contamination exceeding 5% were purified successfully using anti-CD45 and anti-CD105 for negative selection of maternal white blood cells and endothelial mecenchymal cells. Accurate prenatal diagnosis of haemoglobinopathies was achieved in all CF samples containing more than 30 fetal cells. In all 25 cases with an adequate number of fetal cells, the diagnosis was correct and confirmed by CVS, amniocentesis or placental tissue. The low success rate in diagnosis reported in previous studies is the inevitable consequence of failure to firstly, identify and distinguish between foetal and maternal cells and secondly, develop an effective method for removal of the maternal cells (Jouannic et al, 2006 (Jouannic et al, , 2008 .
The CF contains embryo-fetal erythroid precursors or megaloblasts (Migliaccio et al, 1986; Renda et al, 2010) . Haematopoiesis in the embryo starts in the 2nd or 3rd week of gestation when yolk sac blood islands develop clones of primitive nucleated erythroblasts or megaloblasts (Valtieri et al, 1989; Stamatoyannopoulos, 2005; Zambidis et al, 2005) . Detailed analysis of these embryonic cells revealed a prevalent megaloblast pattern with CD71+/CD45) membrane expression, consistent with embryonic erythroid precursors (Migliaccio et al, 1986) . The presence of such precursors in CF may infer that there is cellular trafficking between the embryo and the celomic cavity. In theory, the possibility of early access to the celomic cavity in combination with the cell trafficking between the embryonal compartments could also allow a novel strategy for in utero cell transplantation (Noia et al, 2004) .
This study has shown that reliable molecular diagnosis is possible from CF provided the sample contains at least 30 fetal cells. Future studies will determine the feasibility of prenatal diagnosis in CF samples containing less fetal cells by employing specific selection of such cells directly under the microscope and the application of techniques similar to those used in preimplantation diagnosis. Ultimately, widespread clinical application of celocentesis will need to await the results of ongoing studies on the safety of this technique.
